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We examined whether two functional polymorphisms (g.-1306 C>T and g.-735 C>T) in matrix metallopro-
teinase (MMP)-2 gene are associated with preeclampsia (PE) or gestational hypertension (GH), and whether
they modify MMP-2 or tissue inhibitor of metalloproteinase (TIMP)-2 plasma concentrations in these hyper-
tensive disorders of pregnancy. We studied 130 healthy pregnant (HP), 130 pregnant with GH, and 133 preg-
nant with PE. Genomic DNAwas extracted from whole blood and genotypes for g.-1306 C>T and g.-735 C>T
polymorphisms were determined by Real Time-PCR, using Taqman allele discrimination assays. Haplotypes
were inferred using the PHASE program. Plasma MMP-2 and TIMP-2 concentrations were measured by
ELISA. The main ﬁndings were that pregnant with PE have higher plasma MMP-2 and TIMP-2 concentrations
than HP (Pb0.05), although the MMP-2/TIMP-2 ratios were similar (P>0.05). Moreover, pregnant with GH
have elevated plasma MMP-2 levels and MMP-2/TIMP-2 ratios compared to HP (Pb0.05). While MMP-2
genotypes and haplotypes are not linked with hypertensive disorders of pregnancy, MMP-2 genotypes and
haplotypes are associated with signiﬁcant alterations in plasma MMP-2 and TIMP-2 concentrations in pre-
eclampsia (Pb0.05). Our ﬁndings may help to understand the relevance of MMP-2 and its genetic polymor-
phisms to the pathophysiology of hypertensive disorders of pregnancy. It is possible that patients with PE and
the MMP-2 haplotype combining the C and T alleles for the g.-1306 C>T and g.-735 C>T polymorphisms
may beneﬁt from the use of MMPs inhibitors such as doxycycline. However, this possibility remains to be
determined.
© 2012 Elsevier Inc. All rights reserved.
Introduction
Preeclampsia affects 3–5% of pregnancies worldwide and in-
creases maternal–fetal morbidity and mortality (WHO, 2005). This
disorder increases the risk of cardiovascular events later in the lives
of mothers and children (Kajantie et al., 2009; Wilson et al., 2003).
While the underlying etiology of this condition remains unknown, re-
duced placental perfusion induces the release of biomolecules by the
placenta into the maternal circulation, thus causing endothelial dys-
function (Myers et al., 2005a; Roberts and Gammill, 2005). Early in
normal pregnancy, cytotrophoblasts migrate towards the uterine spi-
ral arterioles and differentiate into endothelial cells, and these pro-
cesses involve activation of matrix metalloproteinases (MMPs) with
modiﬁcations of extracellular matrix components (Damsky et al.,
1992). The physiologic remodeling of the endothelial layer and de-
struction of elastic-muscular vascular tissues increase the blood sup-
ply to the developing fetus. However, the invasion of spiral arteries in
preeclampsia is limited, thus reducing uteroplacental perfusion and
causing ischemia of the placenta (Meekins et al., 1994).
MMPs are a family of structurally related, zinc-dependent en-
zymes that break down several extracellular matrix components,
such as collagen, elastin, and laminin (Visse and Nagase, 2003). Im-
paired MMP activity is involved in many clinical conditions affecting
the cardiovascular system including hypertensive disorders of preg-
nancy(Montagnana et al., 2009; Myers et al., 2005b; Narumiya et al.,
2001; Palei et al., 2008; Tayebjee et al., 2005). Speciﬁcally, MMP-2
may be involved in uteroplacental artery remodeling and control of
cytotrophoblastic invasion (Isaka et al., 2003; Shimonovitz et al.,
1994). Upregulated MMP-2 may interact with circulating factors
associated with oxidative stress and inﬂammation to produce the
endothelial dysfunction seen in preeclampsia (Sankaralingam et al.,
2006).
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MMP-2 activity is regulated at different levels including its tran-
scription, activation of its latent form, and endogenous inhibition
mainly by the tissue inhibitor of metalloproteinase (TIMP)-2
(Lambert et al., 2004). While two functional genetic polymorphisms
in the promoter region of MMP-2 gene (g.-1306 C>T and g.-
735 C>T) may affect MMP-2 expression and activity (Price et al.,
2001; Yu et al., 2004), and therefore promote cardiovascular diseases
(Lacchini et al., in press; Mizon-Gerard et al., 2004), no previous study
has studied MMP-2 gene polymorphisms in hypertensive disorders of
pregnancy.
In the present study, we aimed to verify whether these functional
MMP-2 genetic polymorphisms (and MMP-2 haplotypes) are associ-
ated with preeclampsia or gestational hypertension. Furthermore,
we examined whether these polymorphisms (and MMP-2 haplo-
types) affect the circulating MMP-2 and TIMP-2 levels, and MMP-2/
TIMP-2 ratio (an index of net MMP-2 activity) in patients with
these hypertensive disorders of pregnancy.
Materials and methods
Subjects
Approval for use of human subjects was obtained from the Institu-
tional Review Board at the Faculty of Medicine of Ribeirao Preto
(FMRP), University of Sao Paulo, Brazil, and subjects gave informed
consent. The procedures followed were in accordance with institu-
tional guidelines. All volunteers were consecutively enrolled in the
Department of Obstetrics and Gynecology, University Hospital of the
FMRP. We studied 393 pregnants (130 healthy womenwith uncompli-
cated pregnancies, 130 women with gestational hypertension and 130
womenwith preeclampsia). Hypertensive disorderswere deﬁned in ac-
cordance to the NHBPEP (National High Blood Pressure Education
Program Working Group on High Blood Pressure in Pregnancy)
(2000). Gestational hypertension (GH) was deﬁned as pregnancy-
induced hypertension (≥140 mm Hg systolic or ≥90 mm Hg diastolic
blood pressure on 2 or more measurements at least 6 h apart) in a
woman after 20 weeks of gestation, and returning to normal by
12 weeks post-partum. Preeclampsia (PE) was deﬁned as gestational
hypertension plus signiﬁcant proteinuria (≥0.3 g/24 h). No women
with pre-existing hypertension, with or without superimposed pre-
eclampsia, or with other comorbidity (nephropathies, coagulopathies,
etc.) were included in the study.
At the time of clinic attendance, maternal venous blood samples
were collected. Genomic DNA was extracted from the cellular compo-
nent of 1 mL of whole blood in EDTA by a salting-out method and
stored at −20 °C until analyzed. Plasma was obtained by centrifuga-
tion of whole blood in heparin at 2000×g for 10 min and stored at
−70 °C until assayed.
Genotyping
Genotypes for g.-1306 C>T (rs243865) and g.-735 C>T (rs2285053)
polymorphisms were determined by real time-polymerase chain reac-
tion (RT-PCR), using Taqman Allele Discrimination assays (Applied Bio-
systems, Carlsbad/CA/USA) (Lacchini et al., 2011). Probes and primers
for genotyping of the g.-1306 C>T polymorphism were customized
as follows: forward 5′-GCCATTGTCAATGTTCCCTAAAACA-3′, reverse
5′-TGACTTCTGAGCTGAGACCTGAA-3′ and probes 5′-CAGCACTC[T/C]
ACCTCT-3′. Probes and primers for genotyping of the g.-735 C>T poly-
morphism were designed by Applied Biosystems (ID: C_26734093-20).
TaqMan PCR was performed in a total volume of 12 μL (3 ng of DNA,
1× TaqMan master mix, 1× assay mix) placed in 96-well PCR plates.
Fluorescence from PCR ampliﬁcation was detected using Chromo 4
Detector (Bio-Rad Laboratories, Hercules/CA/USA) and analyzed with
manufacturer's software.
Enzyme immunoassays of plasma MMP-2 and TIMP-2
Plasma MMP-2 and TIMP-2 concentrations were measured by
sandwich ELISA methods with commercially available kits (DMP2F0
and DY971, respectively; R&D Systems, Minneapolis, MN, USA)
according to manufacturer's instructions.
Statistical analysis
The clinical and laboratorial characteristics of women with GH or
PE were compared with those of healthy pregnant women (HP) by
unpaired Student's t-test for parametric data, by Mann–Whitney U-
test for non-parametric data, and by chi-squared test for nominal
data. The distribution of genotypes for each polymorphism was
assessed for deviation from the Hardy–Weinberg equilibrium, and
differences in genotype and allele frequencies among groups were
assessed using chi-squared or Fisher exact tests. The inﬂuence of the
MMP-2 polymorphisms on plasma MMP-2 concentrations in HP, GH
and PE groups was assessed by two-way ANOVA test. A value of
Pb0.05 was considered statistically signiﬁcant.
The Bayesian statistical based program PHASE 2.1 (Stephens and
Scheet, 2005) was used to estimate the haplotype frequencies in
each group. The possible haplotypes including genetic variants for
two MMP-2 polymorphisms studied (C or T variants for the g.-
1306 C>T and C or T variants for g.-735 C>T) were: H1 (C C), H2
(C T), H3 (T C) and H4 (T T). Differences in haplotype frequency
were further tested using contingency tables. We excluded the rare
haplotype (H4 frequency b0.1%) from analysis.
Results
The clinical and laboratorial characteristics of all volunteers en-
rolled in the study are summarized in Supplementary Table 1.
Healthy pregnant (HP), gestational hypertensive (GH) and pre-
eclamptic (PE) women showed similar age, ethnicity, smoking status,
heart rate, fasting glucose, hemoglobin, hematocrit, creatinine, % pri-
miparity, and gestational age at sampling (all P>0.05). As expected,
PE and GH had higher systolic and diastolic blood pressure compared
with HP (all Pb0.05). Higher body mass index (BMI) was found in GH
compared with HP (Pb0.05). Signiﬁcant proteinuria was found in PE.
Lower gestational age at delivery and newborn weight were found in
GH and PE compared with HP (all Pb0.05).
While we found higher plasmaMMP-2 and TIMP-2 concentrations
in PE patients compared with HP (Fig. 1, both Pb0.05), the MMP-2/
TIMP-2 ratios were not different (Fig. 1, P>0.05). Plasma MMP-2
levels and MMP-2/TIMP-2 ratios were elevated in GH patients com-
pared with HP (Fig. 1, both Pb0.05). However, plasma TIMP-2 con-
centrations were similar in GH and HP groups (Fig. 1, P>0.05).
The results of the MMP-2 single-locus analysis are shown in
Supplementary Table 2. The genotype distribution for the two poly-
morphisms studied showed no deviation from Hardy–Weinberg
equilibrium (all P>0.05). We found no signiﬁcant differences in the
genotype or allele frequencies distributions for both MMP-2 polymor-
phisms when GH or PE patients were compared with HP (all P>0.05).
In line with these results, the haplotype analysis showed no signiﬁ-
cant differences in haplotype distributions when GH or PE patients
were compared with HP (all P>0.05; Supplementary Table 3).
We determined the inﬂuence of the g.-1306 C>T and the g.-
735 C>T polymorphisms on plasma MMP-2 and TIMP-2 levels in
GH and PE patients. As highlighted in Fig. 2, PE was associated with
higher MMP-2 and TIMP-2 concentrations (Figs. 2–4, all Pb0.05),
but not MMP-2/TIMP ratios (Figs. 2–4, all P>0.05), when stratiﬁed
by genotypes for both polymorphisms and by haplotypes. However,
GH was signiﬁcantly associated with higher MMP-2 concentrations
and MMP-2/TIMP-2 ratios only when stratiﬁed by haplotypes
(Fig. 4, both Pb0.05). In addition, these analyses showed no
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signiﬁcant effects of the g.-1306 C>T and the g.-735 C>T polymor-
phisms on MMP-2 concentrations or on MMP-2/TIMP-2 ratios in GH
and PE groups compared with HP (Figs. 2 and 3; all P>0.05). Interest-
ingly, the g.-1306 C>T polymorphism affected TIMP-2 concentra-
tions in the PE group (Fig. 2B, P>0.05), and the use of the
Bonferroni post-test revealed that the CC and CT genotypes were as-
sociated with higher TIMP-2 levels in PE compared with HP
(Pb0.001 and Pb0.05, respectively). While we observed no effects
of the g.-735 C>T polymorphism on TIMP-2 concentrations in the
GH and PE groups (Fig. 3; both P>0.05), we found a signiﬁcant inter-
action between the g.-735 C>T polymorphism and PE in determining
MMP-2 concentrations (Fig. 3, Pb0.05), with higher MMP-2 levels in
PE patients carrying CT/TT genotypes. Moreover, while we found no
signiﬁcant effects of MMP-2 haplotypes on MMP-2 and TIMP-2 levels
in GH (Fig. 4; all P>0.05), MMP-2 haplotypes affected MMP-2 and
TIMP-2 concentrations (Fig. 4, both Pb0.05), but not MMP-2/TIMP-2
ratio (Fig. 4, P>0.05) in the PE group. Bonferroni post-tests revealed
that H1, H2 and H3 were associated with higher MMP-2 (Pb0.001,
Pb0.001 and Pb0.01, respectively) and TIMP-2 (Pb0.001, Pb0.001
and Pb0.05, respectively) levels in PE patients compared with HP.
Discussion
MMPs are essential players in embryogenesis (Vu and Werb,
2000) and angiogenesis (Roy et al., 2006). Given the relevance of
MMP-2 for both processes during healthy pregnancy, functional poly-
morphisms in MMP-2 gene could affect the susceptibility to hyper-
tensive disorders of pregnancy. The main ﬁndings reported here
were that women with preeclampsia have higher plasma MMP-2
and TIMP-2 concentrations than healthy pregnant, although the
MMP-2/TIMP-2 ratios were similar. Moreover, women with gesta-
tional hypertension have elevated plasma MMP-2 levels and MMP-
2/TIMP-2 ratios. While MMP-2 genotypes and haplotypes are not
linked with hypertensive disorders of pregnancy, MMP-2 genotypes
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Fig. 1. Plasma MMP-2 (panel A) and TIMP-2 (panel B) concentrations, and MMP-2/
TIMP-2 ratios (panel C) in healthy pregnant (HP), gestational hypertension (GH), and
preeclampsia (PE). The bars show the mean±S.D. P-values are from analysis of GH
or PE group vs. HP group by unpaired Student's t-test.
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Fig. 2. Effects of the g.-1306 C>T MMP-2 polymorphism on plasma MMP-2 (panel A)
and TIMP-2 (panel B) concentrations, and MMP-2/TIMP-2 ratios (panel C) in healthy
pregnant (HP), gestational hypertension (GH), and preeclampsia (PE). The bars show
the mean±S.D. P-values are from analysis of GH or PE group vs. HP group by two-way
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and haplotypes are associated with signiﬁcant alterations in plasma
MMP-2 and TIMP-2 concentrations in preeclampsia.
The increased MMP-2 concentrations in preeclampsia agree with
results previously reported (Montagnana et al., 2009; Myers et al.,
2005b; Narumiya et al., 2001). Although the increased TIMP-2 con-
centrations that we found in preeclampsia contrast with previous
results (Montagnana et al., 2009), our ﬁndings align with similar ﬁnd-
ings reported in another cross-sectional study (Tayebjee et al., 2005).
It is possible that differences in the methods used to measure MMP-2
(ELISA vs. zymography), or differences between patients or gestation-
al ages at sampling may explain the inconsistencies between studies
(Montagnana et al., 2009; Myers et al., 2005b).
The balance between MMP-2 and TIMP-2 is likely to play a major
role in the remodeling of spiral arteries during pregnancy, and it may
be a means by which cytotrophoblastic invasion is controlled (Isaka
et al., 2003; Shimonovitz et al., 1994). Moreover, increased MMP-2
levels may contribute to vascular dysfunction (Castro et al., 2008,
2010) secondary to hypertension-related mechanical stress on the
vascular wall (Donnelly et al., 2003). Therefore, although we have
not assessed vascular MMP-2 levels in the present study, the higher
MMP-2/TIMP-2 ratios that we found in gestational hypertension
may well reﬂect these mechanisms.
This is the ﬁrst study to examine the association of MMP-2 poly-
morphisms with hypertensive disorders of pregnancy. The lack of
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signiﬁcant association between genotypes or haplotypes for the twopoly-
morphisms and preeclampsia or gestational hypertension suggests that
genetic variations in MMP-2 do not affect the susceptibility to these dis-
eases, and is supported by previous ﬁndings showing that the g.-
1306 C>T and g.-735 C>T polymorphisms are not associated with
chronic hypertension (Lacchini et al., in press). However, the prevalence
of intrauterine growth restriction, a common condition in preeclamptic
patients, was affected by the g.-1306 C>T polymorphism (Gremlich et
al., 2007), thus suggesting variable effects for MMP-2 polymorphisms
according to location or clinical condition. It is possible that fetal geno-
types affect the susceptibility to gestational hypertensionor preeclampsia,
and this issue should be addressed in further studies.
The g.-1306 C>T polymorphism affected the circulating TIMP-2
levels, and MMP-2 haplotypes affected plasma MMP-2 and TIMP-2
levels in preeclampsia. These ﬁndings are consistent with in vitro
studies suggesting functional implications for g.-1306 C>T and g.-
735 C>T polymorphisms (Price et al., 2001; Yu et al., 2004). In fact,
the g.-1306 C>T polymorphism disrupts a Sp1-type promoter site,
thus signiﬁcantly changing MMP-2 promoter activity (Price et al.,
2001; Yu et al., 2004). Moreover, the MMP-2 haplotype combining
the C alleles for both polymorphisms causes remarkable increases in
MMP-2 transcription levels(Yu et al., 2004). While our ﬁndings
showed higher MMP-2 levels in preeclampsia associated with the
haplotype combining the C and T alleles for the g.-1306 C>T and g.-
735 C>T polymorphisms, respectively, it is possible that other factors
may play a role in preeclampsia and interact with these genetic
markers in such a way that the higher MMP-2 levels are not associat-
ed with the haplotype combining both C alleles. Unfortunately, none
of the functional studies has studied the effect of MMP-2 polymor-
phisms on TIMP-2 levels. While our results may not be totally consis-
tent with the previous molecular ﬁndings discussed above (Price et
al., 2001; Yu et al., 2004), little is known about the complex regulation
of MMPs, especially MMP-2, in hypertensive disorders of pregnancy,
and in vivo clinical ﬁndings may differ signiﬁcantly from in vitro mo-
lecular studies.
In conclusion, we found evidence that preeclampsia is associated
with increased circulating levels of MMP-2 and TIMP-2, whereas ges-
tational hypertension increases MMP-2 levels and MMP-2/TIMP-2
ratios. Moreover, MMP-2 gene variants are associated with altered
MMP-2 and TIMP-2 concentrations in preeclampsia. It is possible
that these ﬁndings may help to identify patients that would beneﬁt
from the use of MMPs inhibitors.
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